Leishmaniasis is a tropical infectious disease caused by the protozoan Leishmania parasite.
The disease is transmitted by female sand flies and, depending on the infecting parasite …

New drugs are needed to control leishmaniasis and efforts are currently on-going to counter
the neglect of this disease. We discuss here the utility and the impact of associating drug …

Leishmania donovani causes visceral leishmaniasis (VL), the second most deadly vector-
borne parasitic disease. A recent epidemic in the Indian subcontinent (ISC) caused up to …

Background Miltefosine (MIL) is an oral antileishmanial drug used for treatment of visceral
leishmaniasis (VL) in the Indian subcontinent. Recent reports indicate a significant decline in …

Leishmaniasis is a serious medical issue in many countries around the World, but it remains
largely neglected in terms of research investment for developing new control and treatment …

In this study, we followed the genomic, lipidomic and metabolomic changes associated with
the selection of miltefosine (MIL) resistance in two clinically derived Leishmania donovani …

The evolution of drug-resistance in pathogens is a major global health threat. Elucidating the
molecular basis of pathogen drug-resistance has been the focus of many studies but rarely …

The molecular mechanism of antimony-resistant Leishmania donovani (SbRLD)–driven up-
regulation of IL-10 and multidrug-resistant protein 1 (MDR1) in infected macrophages (Mϕs) …

Leishmaniasis is an epidemic in various countries, and the parasite Leishmania donovani is
developing resistance against available drugs. In the present study the antileishmanial …

Visceral leishmaniasis affects people from 70 countries worldwide, mostly from Indian,
African and south American continent. The increasing resistance to antimonial, miltefosine …